NURS 572 EXAM 1 TEST BANK 200
ADVANCED PHARMACOTHERAPEUTICS
QUESTIONS WITH COMPLETE RATIONALES
AND VERIFIED ANSWERS
This premium 200-question test bank offers a comprehensive, high-yield practice
resource specifically engineered for graduate-level advanced practice nursing
students tackling Exam 1. Every multiple-choice question features an italicized
answer key paired with a bold-italic clinical rationale, covering critical topics
from complex pharmacokinetics to autonomic nervous system pharmacology.
Perfect for rapid active recall, this study guide simplifies difficult drug
mechanisms and clinical calculations to guarantee mastery and maximize exam
performance.
Module 1: Pharmacokinetics & Pharmacodynamics (Questions 1–15)
1. A patient with severe chronic kidney disease requires a maintenance dose
of a drug primarily excreted by the kidneys. How should the clinician adjust
the prescription?
o A) Increase the dosage interval.
o B) Decrease the dosage interval.
o C) Increase the individual dose amount.
o D) Maintain standard dosing guidelines.
, o Answer: A
o Rationale: Renal impairment reduces drug clearance, prolonged
half-life, and increases toxicity risks; increasing the dosage interval
or reducing the dose size prevents toxic accumulation.
2. Which process describes the movement of a drug from its site of
administration into the central blood circulation?
o A) Distribution
o B) Absorption
o C) Metabolism
o D) Elimination
o Answer: B
o Rationale: Absorption is the specific pharmacokinetic phase
describing a drug's travel from the administration site into systemic
circulation.
3. An advanced practice nurse administers a highly protein-bound drug to a
patient with severe hypoalbuminemia. What is the primary clinical
consequence?
o A) Decreased therapeutic effect of the drug.
o B) Increased concentration of free active drug.
o C) Accelerated hepatic clearance of the drug.
o D) Decreased volume of distribution.
o Answer: B
o Rationale: Low albumin leaves fewer binding sites available,
resulting in a higher concentration of unbound, pharmacologically
active free drug, which significantly increases toxicity risks.
4. What occurs when an oral medication undergoes the "first-pass effect"?
, o A) It is extensively bound to plasma proteins during first-pass delivery.
o B) It is rapidly excreted unchanged by the kidneys.
o C) It is metabolized by hepatic enzymes before reaching systemic
circulation.
o D) It undergoes immediate absorption through the gastric mucosa.
o Answer: C
o Rationale: The first-pass effect refers to hepatic metabolism of an
orally administered drug absorbed via the portal system before it
can distribute to the rest of the body.
5. A drug has a half-life of 6 hours. Assuming first-order kinetics, how long will
it take to reach steady-state concentrations?
o A) 6 hours
o B) 12 to 18 hours
o C) 24 to 30 hours
o D) 48 to 60 hours
o Answer: C
o Rationale: It takes approximately 4 to 5 half-lives to reach steady-
state serum concentration. For a 6-hour half-life, 4 x 6 = 24 hours,
and 5 x 6 = 30 hours.
6. Which parameter directly measures a drug's safety margin by comparing
therapeutic dose to lethal or toxic dose?
o A) Efficacy index
o B) Bioavailability factor
o C) Therapeutic index
o D) Clearance rate
, o Answer: C
o Rationale: The therapeutic index (TI) is the ratio between a drug's
toxic dose and its effective dose; a narrow TI demands strict serum
monitoring.
7. If a drug behaves as a potent cytochrome P450 (CYP3A4) enzyme inhibitor,
what happens to a co-administered substrate of CYP3A4?
o A) Its plasma levels will decrease drastically.
o B) Its plasma levels will elevate, increasing toxicity risks.
o C) Its therapeutic efficacy will immediately drop.
o D) Its renal clearance rate will double.
o Answer: B
o Rationale: Enzyme inhibitors slow down the metabolism of
substrate drugs, leading to elevated serum concentrations and
heightened toxic risks.
8. A patient is prescribed an enteric-coated medication. What guidance must
the nurse practitioner provide?
o A) Crush the medication if swallowing becomes difficult.
o B) Take the medication exclusively with acidic citrus juices.
o C) Swallow the medication whole without crushing or chewing.
o D) Dissolve the medication completely under the tongue.
o Answer: C
o Rationale: Enteric coatings protect the drug from stomach acid or
protect the stomach from the drug; crushing destroys this
mechanism and alters intended pharmacokinetic absorption.
9. Which mechanism describes a drug that binds to a receptor and produces a
submaximal physiological response compared to a full agonist?
ADVANCED PHARMACOTHERAPEUTICS
QUESTIONS WITH COMPLETE RATIONALES
AND VERIFIED ANSWERS
This premium 200-question test bank offers a comprehensive, high-yield practice
resource specifically engineered for graduate-level advanced practice nursing
students tackling Exam 1. Every multiple-choice question features an italicized
answer key paired with a bold-italic clinical rationale, covering critical topics
from complex pharmacokinetics to autonomic nervous system pharmacology.
Perfect for rapid active recall, this study guide simplifies difficult drug
mechanisms and clinical calculations to guarantee mastery and maximize exam
performance.
Module 1: Pharmacokinetics & Pharmacodynamics (Questions 1–15)
1. A patient with severe chronic kidney disease requires a maintenance dose
of a drug primarily excreted by the kidneys. How should the clinician adjust
the prescription?
o A) Increase the dosage interval.
o B) Decrease the dosage interval.
o C) Increase the individual dose amount.
o D) Maintain standard dosing guidelines.
, o Answer: A
o Rationale: Renal impairment reduces drug clearance, prolonged
half-life, and increases toxicity risks; increasing the dosage interval
or reducing the dose size prevents toxic accumulation.
2. Which process describes the movement of a drug from its site of
administration into the central blood circulation?
o A) Distribution
o B) Absorption
o C) Metabolism
o D) Elimination
o Answer: B
o Rationale: Absorption is the specific pharmacokinetic phase
describing a drug's travel from the administration site into systemic
circulation.
3. An advanced practice nurse administers a highly protein-bound drug to a
patient with severe hypoalbuminemia. What is the primary clinical
consequence?
o A) Decreased therapeutic effect of the drug.
o B) Increased concentration of free active drug.
o C) Accelerated hepatic clearance of the drug.
o D) Decreased volume of distribution.
o Answer: B
o Rationale: Low albumin leaves fewer binding sites available,
resulting in a higher concentration of unbound, pharmacologically
active free drug, which significantly increases toxicity risks.
4. What occurs when an oral medication undergoes the "first-pass effect"?
, o A) It is extensively bound to plasma proteins during first-pass delivery.
o B) It is rapidly excreted unchanged by the kidneys.
o C) It is metabolized by hepatic enzymes before reaching systemic
circulation.
o D) It undergoes immediate absorption through the gastric mucosa.
o Answer: C
o Rationale: The first-pass effect refers to hepatic metabolism of an
orally administered drug absorbed via the portal system before it
can distribute to the rest of the body.
5. A drug has a half-life of 6 hours. Assuming first-order kinetics, how long will
it take to reach steady-state concentrations?
o A) 6 hours
o B) 12 to 18 hours
o C) 24 to 30 hours
o D) 48 to 60 hours
o Answer: C
o Rationale: It takes approximately 4 to 5 half-lives to reach steady-
state serum concentration. For a 6-hour half-life, 4 x 6 = 24 hours,
and 5 x 6 = 30 hours.
6. Which parameter directly measures a drug's safety margin by comparing
therapeutic dose to lethal or toxic dose?
o A) Efficacy index
o B) Bioavailability factor
o C) Therapeutic index
o D) Clearance rate
, o Answer: C
o Rationale: The therapeutic index (TI) is the ratio between a drug's
toxic dose and its effective dose; a narrow TI demands strict serum
monitoring.
7. If a drug behaves as a potent cytochrome P450 (CYP3A4) enzyme inhibitor,
what happens to a co-administered substrate of CYP3A4?
o A) Its plasma levels will decrease drastically.
o B) Its plasma levels will elevate, increasing toxicity risks.
o C) Its therapeutic efficacy will immediately drop.
o D) Its renal clearance rate will double.
o Answer: B
o Rationale: Enzyme inhibitors slow down the metabolism of
substrate drugs, leading to elevated serum concentrations and
heightened toxic risks.
8. A patient is prescribed an enteric-coated medication. What guidance must
the nurse practitioner provide?
o A) Crush the medication if swallowing becomes difficult.
o B) Take the medication exclusively with acidic citrus juices.
o C) Swallow the medication whole without crushing or chewing.
o D) Dissolve the medication completely under the tongue.
o Answer: C
o Rationale: Enteric coatings protect the drug from stomach acid or
protect the stomach from the drug; crushing destroys this
mechanism and alters intended pharmacokinetic absorption.
9. Which mechanism describes a drug that binds to a receptor and produces a
submaximal physiological response compared to a full agonist?
